Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS

Niall Stewart(Royal Children's Hospital), Bruce Taylor(University of London), Fotini Pittas(University of Tasmania), Steve Simpson(University of Tasmania), Ingrid van der Mei(University of Tasmania), Anne‐Louise Ponsonby(Royal Children's Hospital), Pauline Ko(Royal Children's Hospital), Leigh Blizzard(University of Tasmania), T Dwyer(Murdoch Children's Research Institute), Darryl W. Eyles(The University of Queensland)
Neurology
June 15, 2012
10.1212/wnl.0b013e31825fded9
Cited by 96

Related Papers

Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition
|Multiple Sclerosis Journal|2020|2.5k
Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data
|BMJ|2017|2.1k
Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity
|Neurology|2014|1.3k
Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants
|Journal of Allergy and Clinical Immunology|2011|1k
Higher 25‐hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis
|Annals of Neurology|2010|453